title: Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma.
abstract: OBJECTIVE
  To evaluate the therapeutic efficacy of transcatheter arterial chemoembolization (TACE) using miriplatin emulsion in unresectable hepatocellular carcinoma (HCC).
  
  
  METHODS
  The efficacy of TACE was evaluated by dynamic computed tomography or magnetic resonance imaging three months after TACE, according to the Response Evaluation Criteria in Cancer Study Group of Japan (RECICL). Adverse events were assessed using Common Terminology Criteria, version 4.0.
  
  
  RESULTS
  Eighteen patients with 48 lesions received TACE with miriplatin-lipiodol (LPD) suspension (miriplatin suspension) and 53 patients with 114 HCC tumors received TACE with miriplatin-LPD water-soluble contrast agent emulsion (miriplatin emulsion). TACE with miriplatin emulsion enabled for administration of a higher dose of miriplatin compared to TACE with miriplatin suspension (p=0.016), although there were no significant differences in the frequency of adverse events between the two groups. The treatment effect per tumor was significantly higher in the emulsion group than in the suspension group (p=0.001). The time-to-progression per tumor was significantly shorter in the suspension group than in the emulsion group (p=0.001).
  
  
  CONCLUSIONS
  TACE with miriplatin emulsion is more effective than that with miriplatin suspension.
authors: Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan. techiba@faculty.chiba-u.jp.
authors: Kenichiro
authors: K
authors: Okimoto
authors: Sadahisa
authors: S
authors: Ogasawara
authors: Tetsuhiro
authors: T
authors: Chiba
authors: Yoshihiko
authors: Y
authors: Ooka
authors: Masamichi
authors: M
authors: Oobu
authors: Ryousaku
authors: R
authors: Azemoto
authors: Naoya
authors: N
authors: Kanogawa
authors: Tenyu
authors: T
authors: Motoyama
authors: Eiichiro
authors: E
authors: Suzuki
authors: Akinobu
authors: A
authors: Tawada
authors: Masaharu
authors: M
authors: Yoshikawa
authors: Osamu
authors: O
authors: Yokosuka
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D002404:Catheterization; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects / Q000379:methods / Q000592:standards*; D003287:Contrast Media / Q000008:administration & dosage*; D004998:Ethiodized Oil / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage*; D012995:Solubility; D014867:Water
chemical_list: D003287:Contrast Media; D009944:Organoplatinum Compounds; D014867:Water; C406530:miriplatin; D004998:Ethiodized Oil
keywords: Hepatocellular carcinoma; emulsion; miriplatin; suspension; transcatheter arterial chemoembolization